These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. Stern PL J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015 [TBL] [Abstract][Full Text] [Related]
3. Vaccines for preventing HPV-related anogenital infection and neoplasia. Ferris DG J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555 [TBL] [Abstract][Full Text] [Related]
4. [Prophylactic and therapeutic vaccine therapy in papillomavirus infections]. Vinatier D; Cosson M; Dufour P Gynecol Obstet Fertil; 2000 May; 28(5):370-84. PubMed ID: 10893881 [TBL] [Abstract][Full Text] [Related]
5. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Ault KA Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901 [TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Tomson TT; Roden RB; Wu TC Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945 [TBL] [Abstract][Full Text] [Related]
7. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983 [TBL] [Abstract][Full Text] [Related]
9. Strategies for the prevention of cervical cancer by human papillomavirus vaccination. Williamson AL; Passmore JA; Rybicki EP Best Pract Res Clin Obstet Gynaecol; 2005 Aug; 19(4):531-44. PubMed ID: 16150392 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology and natural history of genital human papillomavirus infection. Weaver BA J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S2-8. PubMed ID: 16729554 [TBL] [Abstract][Full Text] [Related]
11. Human papillomaviruses and genital disease. Ahmed AM; Madkan V; Tyring SK Dermatol Clin; 2006 Apr; 24(2):157-65, vi. PubMed ID: 16677964 [TBL] [Abstract][Full Text] [Related]
12. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Villa LL Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583 [TBL] [Abstract][Full Text] [Related]
13. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048 [TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus vaccines. Stanley MA Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690 [TBL] [Abstract][Full Text] [Related]
16. Anogenital human papillomavirus infection. Changes in understanding and management. Sellors JW; Law C Can Fam Physician; 1994 Jan; 40():93-101. PubMed ID: 8312760 [TBL] [Abstract][Full Text] [Related]
17. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090 [TBL] [Abstract][Full Text] [Related]
18. [Biology of the papillomavirus infections: V. Vaccine developments]. Seilles E; Riethmuller D; Mougin C Ann Biol Clin (Paris); 1999; 57(5):517-24. PubMed ID: 10518053 [TBL] [Abstract][Full Text] [Related]